Sex steroid receptors in skeletal differentiation and epithelial neoplasia: Is tissue-specific intervention possible?

BioEssays

Volumn 31, Issue 6, 2009, Pages 629-641

  Copland, John A ^a   Sheffield Moore, Melinda ^b   Koldzic Zizanovic, Nina ^c   Gentry, Sean ^d   Lamprou, George ^e   Tzortzatou Stathopoulou, Fotini ^e   Zoumpourlis, Vassilis ^f   Urban, Randall J ^b   Vlahopoulos, Spiros A ^f  

^a MAYO CLINIC   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c University of Charleston   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ATHENS   (Greece)

^f INSTITUTE OF BIOLOGY   (Greece)

Author keywords

Differentiation; Gene expression; Steroid hormone; Steroid receptor; Transcription factor

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BRCA1 PROTEIN; CYCLIN D1; ESTROGEN; ESTROGEN RECEPTOR; FINASTERIDE; LETROZOLE; PROTEIN INHIBITOR OF ACTIVATED STAT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN;

BONE DEVELOPMENT; BONE GROWTH; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CYTOLOGY; DRUG MECHANISM; ENZYME INHIBITION; HORMONE ACTION; HUMAN; MOLECULAR BIOLOGY; MUSCLE DEVELOPMENT; MUSCLE GROWTH; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; TISSUE DIFFERENTIATION; ANIMAL; BONE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; BONE AND BONES; GONADAL STEROID HORMONES; HUMANS; MODELS, MOLECULAR; MUSCLE, SKELETAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OSTEOGENESIS; PROTEIN CONFORMATION; RECEPTORS, STEROID; SIGNAL TRANSDUCTION;

EID: 67650103912     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.200800138     Document Type: Review

References (110)

1. O'Malley, B. W., Mechanisms of action of steroid hormones. N Engl J Med 1971. 284: 370-377.
2. Winter, J. S., Faiman, C. and Reyes, F. I., Sex steroid production by the human fetus: its role in morphogenesis and control by gonadotropins. Birth Defects Orig Artic Ser 1977. 13: 41-58.
3. Hannema, S. E., Print, C. G., Charnock-Jones, D. S., Coleman, N. and Hughes, I. A., Changes in gene expression during Wolffian duct development. Horm Res 2006. 65: 200-209.
4. Couse, J. F. and Korach, K. S., Exploring the role of sex steroids through studies of receptor deficient mice. J Mol Med 1998. 76: 497-511.
5. Ottolenghi, C., Uda, M., Crisponi, L., Omari, S., Cao, A., et al. Determination and stability of sex. BioEssays 2007. 29: 15-25.
6. Renwick, A. G., Metabolism and function of ovarian and testicular hormones. J Reprod Fertil Suppl 1970. 12: 55-64.
7. Schoenau, E., Bone mass increase in puberty: what makes it happen? Horm Res 2006. 65 (Suppl 2), 2-10.
8. Hammond, G. L. and Bocchinfuso, W. P., Sex hormone-binding globulin: gene organization and structure/function analyses. Horm Res 1996. 45: 197-201.
9. van Steensel, B., Jenster, G., Damm, K., Brinkmann, A. O. and van Driel, R., Domains of the human androgen receptor and glucocorticoid receptor involved in binding to the nuclear matrix. J Cell Biochem 1995. 57: 465-478.
10. Eriksson, P., Daneholt, B. and Wrange, O., The glucocorticoid receptor in homodimeric and monomeric form visualised by electron microscopy. J Struct Biol 1991. 107: 48-55.
11. Simental, J. A., Sar, M., Lane, M. V., French, F. S. and Wilson, E. M., Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991. 266: 510-518.
12. Scheller, A., Hughes, E., Golden, K. L. and Robins, D. M., Multiple receptor domains interact to permit, or restrict, androgen-specific gene activation. J Biol Chem 1998. 273: 24216-24222.
13. List, H. J., Lozano, C., Lu, J., Danielsen, M., Wellstein, A., et al. Comparison of chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter by the androgen and glucocorticoid receptor. Exp Cell Res 1999. 250: 414-422.
14. Renoir, J. M., Radanyi, C., Faber, L. E. and Baulieu, E. E., The non-DNA-binding heterooligomeric form of mammalian steroid hormone receptors contains a hsp90-bound 59-kilodalton protein. J Biol Chem 1990. 265: 10740-10745.
15. Wu, Y., Zhao, W., Zhao, J., Pan, J., Wu, Q., et al. Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology 2007. 148: 2984-2993.
16. Maurer, R. A., Selective binding of the estradiol receptor to a region at least one kilobase upstream from the rat prolactin gene. DNA 1985. 4: 1-9.
17. Song, M. R., Lee, S. K., Seo, Y. W., Choi, H. S., Lee, J. W., et al. Differential modulation of transcriptional activity of oestrogen receptors by direct protein-protein interactions with retinoid receptors. Biochem J 1998. 336: 711-717.
18. Eng, F. C., Barsalou, A., Akutsu, N., Mercier, I., Zechel, C., et al. Different classes of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain. J Biol Chem 1998. 273: 28371-28377.
19. Cascio, S., Bartella, V., Garofalo, C., Russo, A., Giordano, A., et al. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J Biol Chem 2007. 282: 3498-3506.
20. Sato, N., Sadar, M. D., Bruchovsky, N., Saatcioglu, F., Rennie, P. S., et al. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c- Jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997. 272: 17485-17494.
21. Weigel, N. L. and Zhang, Y., Ligand-independent activation of steroid hormone receptors. J Mol Med 1998. 76: 469-479.
22. Quayle, S. N. and Sadar, M. D., 14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens. Cancer Lett 2007. 254: 137-145.
23. Ma, Y., Hu, C., Riegel, A. T., Fan, S. and Rosen, E. M., Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol 2007. 21: 1905-1923.
24. Hitosugi, T., Sasaki, K., Sato, M., Suzuki, Y. and Umezawa, Y., Epidermal growth factor directs sex-specific steroid signaling through Src activation. J Biol Chem 2007. 282: 10697-10706.
25. Huang, Z. Q., Li, J. and Wong, J., AR possesses an intrinsic hormone-independent transcriptional activity. Mol Endocrinol 2002. 16: 924-937.
26. Kelly, M. J., Lagrange, A. H., Wagner, E. J. and Ronnekleiv, O. K., Rapid effects of estrogen to modulate G protein-coupled receptors via activation of protein kinase A and protein kinase C pathways. Steroids 1999. 64: 64-75.
27. Watson, C. S., Bulayeva, N. N., Wozniak, A. L. and Finnerty, C. C., Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens. Steroids 2005. 70: 364-371.
28. Koldzic-Zivanovic, N., Seitz, P. K., Watson, C. S., Cunningham, K. A. and Thomas, M. L., Intracellular signaling involved in estrogen regulation of serotonin reuptake. Mol Cell Endocrinol 2004. 226: 33-42.
29. Gavrilova-Jordan, L. P. and Price, T. M., Actions of steroids in mitochondria. Semin Reprod Med 2007. 25: 154-164.
30. Kotaja, N., Vihinen, M., Palvimo, J. J. and Janne, O. A., Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling. J Biol Chem 2002. 277: 17781-17788.
31. Syed, F. and Khosla, S., Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 2005. 328: 688-696.
32. Venken, K., De Gendt, K., Boonen, S., Ophoff, J., Bouillon, R., et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res 2006. 21: 576-585.
33. Heemers, H. V. and Tindall, D. J., Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007. 28: 778-808.
34. Kumar, R., Serrette, J. M., Khan, S. H., Miller, A. L. and Thompson, E. B., Effects of different osmolytes on the induced folding of the Nterminal activation domain (AF1) of the glucocorticoid receptor. Arch Biochem Biophys 2007. 465: 452-460.
35. Kumar, R., Volk, D. E., Li, J., Lee, J. C., Gorenstein, D. G., et al. TATA box binding protein induces structure in the recombinant glucocorticoid receptor AF1 domain. Proc Natl Acad Sci USA 2004. 101: 16425-16430.
36. Yudt, M. R. and Cidlowski, J. A., Molecular identification and characterization of a and b forms of the glucocorticoid receptor. Mol Endocrinol 2001. 15: 1093-1103.
37. Chrousos, G. P. and Kino, T., Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE 2005. 304: p. 48.
38. Jagla, M., Feve, M., Kessler, P., Lapouge, G., Erdmann, E., et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007. 148: 4334-4343.
39. Pace, P., Taylor, J., Suntharalingam, S., Coombes, R. C. and Ali, S., Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem 1997. 272: 25832-25838.
40. Gougelet, A., Bouclier, C., Marsaud, V., Maillard, S., Mueller, S. O., et al. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. J Steroid Biochem Mol Biol 2005. 94: 71-81.
41. Bakas, P., Liapis, A., Vlahopoulos, S., Giner, M., Logotheti, S., et al. Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. Fertil Steril 2008. 90: 1878-1885.
42. Girasole, G., Jilka, R. L., Passeri, G., Boswell, S., Boder, G., et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992. 89: 883-891.
43. Sheffield-Moore, M. and Urban, R. J., An overview of the endocrinology of skeletal muscle. Trends Endocrinol Metab 2004. 15: 110-115.
44. Mauras, N., Growth hormone therapy in the glucocorticosteroid-dependent child: metabolic and linear growth effects. Horm Res 2001. 56 (Suppl 1), 13-18.
45. McMillan, J., Fatehi-Sedeh, S., Sylvia, V. L., Bingham, V., Zhong, M., et al. Sex-specific regulation of growth plate chondrocytes by estrogen is via multiple MAP kinase signaling pathways. Biochim Biophys Acta 2006. 1763: 381-392.
46. Keller, E. T., Chang, C. and Ershler, W. B., Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 1996. 271: 26267-26275.
47. Andela, V. B., Gordon, A. H., Zotalis, G., Rosier, R. N., Goater, J. J., et al. NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res 2003. (415 Suppl): S75-85.
48. Sokoloff, M. H., Tso, C. L., Kaboo, R., Taneja, S., Pang, S., et al. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 1996. 77: 1862-1872.
49. Srivastava, S., Toraldo, G., Weitzmann, M. N., Cenci, S., Ross, F. P., et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 2001. 276: 8836-8840.
50. Vlahopoulos, S. and Zoumpourlis, V. C., JNK: a key modulator of intracellular signalling. Biochemistry (Mosc) 2004. 69: 844-854.
51. Burger, H. G., Androgen production in women. Fertil Steril 2002. 77 (Suppl 4), S3-5.
52. Singh, R., Artaza, J. N., Taylor, W. E., Gonzalez-Cadavid, N. F. and Bhasin, S., Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003. 144: 5081-5088.
53. Lee, D. K., Androgen receptor enhances myogenin expression and accelerates differentiation. Biochem Biophys Res Commun 2002. 294: 408-413.
54. Ferrando, A. A., Sheffield-Moore, M., Yeckel, C. W., Gilkison, C., Jiang, J., et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002. 282: E601-607.
55. Sheffield-Moore, M., Paddon-Jones, D., Casperson, S. L., Gilkison, C., Volpi, E., et al. Androgen therapy induces muscle protein anabolism in older women. J Clin Endocrinol Metab 2006. 91: 3844-3849.
56. Sinha-Hikim, I., Taylor, W. E., Gonzalez-Cadavid, N. F., Zheng, W. and Bhasin, S., Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab 2004. 89: 5245-5255.
57. Hong, M. H., Sun, H., Jin, C. H., Chapman, M., Hu, J., Chang, W., et al. Cell-specific activation of the human skeletal alpha-actin by androgens. Endocrinology 2008. 149: 1103-1112.
58. Rose, A. J., Frøsig, C., Kiens, B., Wojtaszewski, J. F. and Richter, E. A., Effect of endurance exercise training on Ca2R calmodulin-dependent protein kinase II expression and signalling in skeletal muscle of humans. J Physiol 2007. 583: 785-795.
59. Vlahopoulos, S., Zimmer, W. E., Jenster, G., Belaguli, N. S., Balk, S. P., et al. Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. J Biol Chem 2005. 280: 7786-7792.
60. Reid, J., Murray, I., Watt, K., Betney, R. and McEwan, I. J., The androgen receptor interacts with multiple regions of the large subunit of general transcription factor TFIIF. J Biol Chem 2002. 277: 41247-41253.
61. Zhu, H., Joliot, V. and Prywes, R., Role of transcription factor TFIIF in serum response factor-activated transcription. J Biol Chem 1994. 269: 3489-3497.
62. Li, P., Lee, H., Guo, S., Unterman, T. G., Jenster, G., et al. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 2003. 23: 104-118.
63. Thompson, E. B., Stepping stones in the path of glucocorticoid-driven apoptosis of lymphoid cells. Acta Biochim Biophys Sin (Shanghai) 2008. 40: 595-600.
64. Piette, C., Munaut, C., Foidart, J. M. and Deprez, M., Treating gliomas with glucocorticoids: from bedside to bench. Acta Neuropathol 2006. 112: 651-664.
65. Lobanova, Y. S., Scherbakov, A. M., Shatskaya, V. A. and Krasil'nikov, M. A., Mechanism of estrogen-induced apoptosis in breast cancer cells: role of the NF-kappaB signaling pathway. Biochemistry (Mosc) 2007. 72: 320-327.
66. Altuwaijri, S., Lin, H. K., Chuang, K. H., Lin, W. J., Yeh, S., et al. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res 2003. 63: 7106-7112.
67. Rocha, S. and Perkins, N. D., ARF the integrator: linking NF-kappaB, p53 and checkpoint kinases. Cell Cycle 2005. 4: 756-759.
68. Benezra, M., Chevallier, N., Morrison, D. J., MacLachlan, T. K. and El-Deiry, W. S., BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem 2003. 278: 26333-26341.
69. Jang, H. D., Yoon, K., Shin, Y. J., Kim, J. and Lee, S. Y., PIAS3 suppresses NF-kappaB-mediated transcription by interacting with the p65/ RelA subunit. J Biol Chem 2004. 279: 24873-24880.
70. Wang, C., Fan, S., Li, Z., Fu, M., Rao, M., et al. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res 2005. 65: 6557-6567.
71. Petre, C. E., Wetherill, Y. B., Danielsen, M. and Knudsen, K. E., Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 2002. 277: 2207-2215.
72. Mitin, N., Kudla, A. J., Konieczny, S. F. and Taparowsky, E. J., Differential effects of Ras signaling through NFkappaB on skeletal myogenesis. Oncogene 2001. 20: 1276-1286.
73. Park, J. J., Irvine, R. A., Buchanan, G., Koh, S. S., Park, J. M., et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 2000. 60: 5946-5949.
74. Junicho, A., Matsuda, T., Yamamoto, T., Kishi, H., Korkmaz, K., et al. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 2000. 278: 9-13.
75. Wang, L. H., Yang, X. Y., Mihalic, K., Xiao, W., Li, D., et al. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J Biol Chem 2001. 276: 31839-31844.
76. Hu, Y. C., Yeh, S., Yeh, S. D., Sampson, E. R., Huang, J., et al. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem 2004. 279: 33438-33446.
77. Yeh, S., Kang, H. Y., Miyamoto, H., Nishimura, K., Chang, H. C., et al. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine 1999. 11: 195-202.
78. Hodgson, M. C., Astapova, I., Hollenberg, A. N. and Balk, S. P., Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007. 67: 8388-8395.
79. Bramlett, K. S., Dits, N. F., Sui, X., Jorge, M. C., Zhu, X., et al. Repression of androgen-regulated gene expression by dominant negative androgen receptors. Mol Cell Endocrinol 2001. 183: 19-28.
80. Sui, X., Bramlett, K. S., Jorge, M. C., Swanson, D. A., von Eschenbach, A. C., et al. Specific androgen receptor activation by an artificial coactivator. J Biol Chem 1999. 274: 9449-9454.
81. Vickers, M. R., MacLennan, A. H., Lawton, B., Ford, D., Martin, J., et al., WISDOM group. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007. 335: 239.
82. Calof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005. 60: 1451-1457.
83. Kasperk, C. H., Wakley, G. K., Hierl, T. and Ziegler, R., Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res 1997. 12: 464-471.
84. Burger, H.G., Selective oestrogen receptor modulators. Horm Res 2000. 53 (Suppl 3): 25-29.
85. Moggs, J. G., Deavall, D. G. and Orphanides, G., Sex steroids, ANGELS and osteoporosis. BioEssays 2003. 25: 195-199.
86. Manolagas, S. C., Kousteni, S., Chen, J. R., Schuller, M., Plotkin, L., et al. Kinase-mediated transcription, activators of nongenotropic estrogen-like signaling (ANGELS), and osteoporosis: a different perspective on the HRT dilemma. Kidney Int Suppl Oct 2004. S41-49.
87. Aguirre, J. I., Plotkin, L. I., Gortazar, A. R., Millan, M. M., O'Brien, C. A., et al. A novel ligand-independent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. J Biol Chem 2007. 282: 25501-25508.
88. Degtiar, W. G. and Kushlinsky, N. E., 3alpha-Hydroxysteroid dehydrogenase in animal and human tissues. Biochemistry (Mosc) 2001. 66: 256-266.
89. Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005. 90: 1502-1510.
90. Foster, P. A., Steroid metabolism in breast cancer. Minerva Endocrinol 2008. 33: 27-37.
91. Baker, M. E., Evolution of adrenal and sex steroid action in vertebrates: a ligand-based mechanism for complexity. BioEssays 2003. 25: 396-400.
92. Houston, K. D., Copland, J. A., Broaddus, R. R., Gottardis, M. M., Fischer, S. M., et al. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma. Cancer Res 2003. 63: 1221-1227.
93. de Ostrovich, K. K., Lambertz, I., Colby, J. K., Tian, J., Rundhaug, J. E., et al. Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo. Am J Pathol 2008. 173: 824-834.
94. González, C., Díaz, F. and Alonso, A., Neuroprotective effects of estrogens: cross-talk between estrogen and intracellular insulin signalling. Infect Disord Drug Targets 2008. 8: 65-67.
95. Höti, N., Li, Y., Chen, C. L., Chowdhury, W. H., Johns, D. C., et al. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Mol Ther 2007. 15: 1495-1503.
96. Freytag, S. O., Stricker, H., Peabody, J., Pegg, J., Paielli, D., et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007. 15: 636-642.
97. Maitland, N. J. and Collins, A. T., Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008. 26: 2862-2870.
98. Zhou, J., Zhang, H., Gu, P., Bai, J., Margolick, J. B., et al. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2008. 111: 419-427.
99. Shi, X. B., Xue, L., Zou, J. X., Gandour-Edwards, R., Chen, H., et al. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells. Prostate 2008. 68: 1816-1826.
100. Varricchio, L., Migliaccio, A., Castoria, G., Yamaguchi, H., de Falco, A., et al. Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide. Mol Cancer Res 2007. 5: 1213-1221.
101. Li, X., Liu, Y. H., Lee, S. J., Gardner, T. A., Jeng, M. H., et al. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clin Cancer Res 2008. 14: 291-299.
102. Guan, M., Tripathi, V., Zhou, X. and Popescu, N. C., Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: prospects for gene therapy. Cancer Gene Ther 2008. 15: 371-381.
103. Peng, Y., Chen, F., Melamed, J., Chiriboga, L., Wei, J., et al. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci USA 2008. 105: 5236-5241.
104. Boorjian, S., Heemers, H., Frank, I., Farmer, S., Schmidt, L., et al., Expression,significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer 2008. 16: Oct 9.
105. Vlahopoulos, S. A., Logotheti, S., Mikas, D., Giarika, A., Gorgoulis, V., et al. The role of ATF-2 in oncogenesis. BioEssays 2008. 30: 314-327.
106. Saporita, A. J., Ai, J. and Wang, Z., The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 2007. 67: 509-520.
107. Fraser, R. A., Heard, D. J., Adam, S., Lavigne, A. C., Le Douarin, B., et al. The putative cofactor TIF1alpha is a protein kinase that is hyperphosphorylated upon interaction with liganded nuclear receptors. J Biol Chem 1998. 273: 16199-16204.
108. Garside, H., Stevens, A., Farrow, S., Normand, C., Houle, B., et al. Glucocorticoid ligands specify different interactions with NF-kappaB by allosteric effects on the glucocorticoid receptor DNA binding domain. J Biol Chem 2004. 279: 50050-50059.
109. Al-Hendy, A., Lee, E. J., Wang, H. Q. and Copland, J. A., Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 2004. 191: 1621-1631.
110. Young, S. L., Al-Hendy, A. and Copland, J. A., Potential nonhormonal therapeutics for medical treatment of leiomyomas. Semin Reprod Med 2004. 22: 121-130.